{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T01:31:36Z","timestamp":1794274296421,"version":"4.9.0"},"reference-count":20,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100007277","name":"Icahn School of Medicine at Mount Sinai","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007277","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","journal-of-hepatology.eu","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Hepatology"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1016\/j.jhep.2024.01.011","type":"journal-article","created":{"date-parts":[[2024,1,20]],"date-time":"2024-01-20T15:50:05Z","timestamp":1705765805000},"page":"822-825","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":97,"title":["Immunotherapy and transplantation for hepatocellular carcinoma"],"prefix":"10.1016","volume":"80","author":[{"given":"Parissa","family":"Tabrizian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maen","family":"Abdelrahim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9113-886X","authenticated-orcid":false,"given":"Myron","family":"Schwartz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.jhep.2024.01.011_bib1","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/S2468-1253(21)00385-X","article-title":"Neoadjuvant cemiplimab for resectable hepatocellular carcinoma: a single-arm, open-label, phase 2 trial","volume":"7","author":"Marron","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"9","key":"10.1016\/j.jhep.2024.01.011_bib2","first-page":"779","article-title":"Ten-year outcomes of liver transplant and downstaging for hepatocellular carcinoma","volume":"157","author":"Tabrizian","year":"2022","journal-title":"JAMA Surg"},{"issue":"3","key":"10.1016\/j.jhep.2024.01.011_bib3","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1111\/ajt.15617","article-title":"Fatal hepatic necrosis after nivolumab as a bridge to liver transplant for HCC: are checkpoint inhibitors safe for the pretransplant patient?","volume":"20","author":"Nordness","year":"2020","journal-title":"Am J Transpl"},{"issue":"12","key":"10.1016\/j.jhep.2024.01.011_bib4","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1002\/lt.23753","article-title":"Identification of liver transplant candidates with hepatocellular carcinoma and a very low dropout risk: implications for the current organ allocation policy","volume":"19","author":"Mehta","year":"2013","journal-title":"Liver Transpl"},{"issue":"4","key":"10.1016\/j.jhep.2024.01.011_bib5","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1097\/SLA.0000000000003253","article-title":"Pathologic response to pretransplant locoregional therapy is predictive of patient outcome after liver transplantation for hepatocellular carcinoma: analysis from the US multicenter HCC transplant consortium","volume":"271","author":"DiNorcia","year":"2020","journal-title":"Ann Surg"},{"key":"10.1016\/j.jhep.2024.01.011_bib6","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1053\/j.gastro.2021.07.033","article-title":"Down-staging outcomes for hepatocellular carcinoma: results from the multicenter evaluation of reduction in tumor size before liver transplantation (MERITS-LT) consortium","volume":"161","author":"Mehta","year":"2021","journal-title":"Gastroenterology"},{"issue":"10088","key":"10.1016\/j.jhep.2024.01.011_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(17)31046-2","article-title":"Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, noncomparative, phase \u00bd dose escalation and expansion trial","volume":"389","author":"El-Khoueiry","year":"2017","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.jhep.2024.01.011_bib8","doi-asserted-by":"crossref","first-page":"e1026","DOI":"10.1097\/SLA.0000000000005803","article-title":"The high incidence of occult carcinoma in total hepatectomy specimens of patients treated for unresectable colorectal liver metastases with liver","volume":"278","author":"Chavez-Villa","year":"2023","journal-title":"Transpl Ann Surg"},{"key":"10.1016\/j.jhep.2024.01.011_bib9","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.3389\/fimmu.2020.02155","article-title":"The immunological basis of liver allograft rejection","volume":"11","author":"Ronca","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.jhep.2024.01.011_bib10","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.653437","article-title":"Neoadjuvant programmed cell death 1 (PD-1) inhibitor treatment in patients with hepatocellular carcinoma before liver transplant: a cohort study and literature review","volume":"12","author":"Qiao","year":"2021","journal-title":"Front Immunol"},{"issue":"6","key":"10.1016\/j.jhep.2024.01.011_bib11","doi-asserted-by":"crossref","first-page":"3408","DOI":"10.4049\/jimmunol.174.6.3408","article-title":"Role of the programmed death-1 pathway in regulation of alloimmune responses in vivo","volume":"174","author":"Sandner","year":"2005","journal-title":"J Immunol"},{"issue":"10","key":"10.1016\/j.jhep.2024.01.011_bib12","doi-asserted-by":"crossref","first-page":"2575","DOI":"10.1111\/j.1600-6143.2012.04224.x","article-title":"Role of the PD-1 pathway in the immune response","volume":"12","author":"Riella","year":"2012","journal-title":"Am J Transpl"},{"issue":"19","key":"10.1016\/j.jhep.2024.01.011_bib13","doi-asserted-by":"crossref","first-page":"3167","DOI":"10.1200\/JCO.2009.26.7609","article-title":"Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates","volume":"28","author":"Brahmer","year":"2010","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.jhep.2024.01.011_bib14","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1111\/ajt.16448","article-title":"PD-1 inhibitor as bridge therapy to liver transplantation?","volume":"21","author":"Tabrizian","year":"2021","journal-title":"Am J Transpl"},{"issue":"6","key":"10.1016\/j.jhep.2024.01.011_bib15","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1111\/ajt.16965","article-title":"Liver transplantation for hepatocellular carcinoma following checkpoint inhibitor therapy with nivolumab","volume":"22","author":"Schnickel","year":"2022","journal-title":"Am J Transpl"},{"issue":"1","key":"10.1016\/j.jhep.2024.01.011_bib16","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1111\/imr.12824","article-title":"Memory T-cell exhaustion and tolerance in transplantation","volume":"292","author":"Hartigan","year":"2019","journal-title":"Immunol Rev"},{"issue":"9","key":"10.1016\/j.jhep.2024.01.011_bib17","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1111\/ajt.15811","article-title":"Efficacy and tolerance of immune checkpoint inhibitors in transplant patients with cancer: a systematic review","volume":"20","author":"d\u2019Izarny-Gargas","year":"2020","journal-title":"Am J Transpl"},{"issue":"9","key":"10.1016\/j.jhep.2024.01.011_bib18","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1034\/j.1600-6143.2002.20908.x","article-title":"Evolution of the enzyme-linked immunosorbent spot assay for post-transplant alloreactivity as a potentially useful immune monitoring tool","volume":"2","author":"Gebauer","year":"2002","journal-title":"Am J Transpl"},{"issue":"16","key":"10.1016\/j.jhep.2024.01.011_bib19","doi-asserted-by":"crossref","first-page":"2918","DOI":"10.1016\/j.cell.2022.06.018","article-title":"Tissue-resident memory and circulating T cells are early responders to pre-surgical cancer immunotherapy","volume":"185","author":"Luoma","year":"2022","journal-title":"Cell"},{"issue":"5","key":"10.1016\/j.jhep.2024.01.011_bib20","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1097\/LVT.0000000000000087","article-title":"Feasibility, safety, and outcome of second-line nivolumab\/bevacizumab in liver transplant patients with recurrent hepatocellular carcinoma","volume":"29","author":"Di Marco","year":"2023","journal-title":"Liver Transpl"}],"container-title":["Journal of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827824000539?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827824000539?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,4,17]],"date-time":"2024-04-17T03:22:30Z","timestamp":1713324150000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168827824000539"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":20,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["S0168827824000539"],"URL":"https:\/\/doi.org\/10.1016\/j.jhep.2024.01.011","relation":{},"ISSN":["0168-8278"],"issn-type":[{"value":"0168-8278","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunotherapy and transplantation for hepatocellular carcinoma","name":"articletitle","label":"Article Title"},{"value":"Journal of Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhep.2024.01.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}